To estimate the potential 10-year Medicare budget impact of expanded access to GLP-1 receptor agonists (GLP-1RAs) for obesity treatment under Most Favored Nation (MFN) pricing, specifically focusing on how this pricing model may increase accessibility.
Key Findings:
Projected Medicare spending on GLP-1RAs for obesity treatment at $245/month is $73.9 billion over 10 years, highlighting the financial burden on the Medicare system.
Health care cost savings from clinical benefits are estimated at $56.3 billion, leading to a net increased spending of $17.6 billion, which raises concerns about sustainability.
Net spending varies significantly with treatment uptake, ranging from $5.0 billion at 10% uptake to $55.4 billion at 90% uptake, indicating the critical role of patient engagement.
Interpretation:
The MFN pricing for GLP-1RAs will likely increase Medicare drug spending, with only partial offsets from health care savings, suggesting that careful monitoring and adjustments may be necessary to achieve cost neutrality.
Limitations:
Estimates do not include costs for additional clinical visits and laboratory monitoring during GLP-1RA initiation and follow-up, which could further impact overall costs.
Further evidence is needed on the impact of GLP-1RAs on health care utilization among obesity-only populations, as individual responses to treatment may vary significantly.
Conclusion:
Alternative strategies for weight maintenance and cost reduction, such as dose adjustments, transitioning to lower-cost medications, or implementing structured behavioral programs, should be evaluated, and policy uncertainties regarding MFN pricing and its implementation remain significant.
